Columbus, OH – PharmaForce Inc., a privately held pharmaceutical R&D and manufacturing company, will expand two of its existing facilities in the Columbus Region, investing approximately $145 million and creating 80 new jobs. Construction and remodeling will commence in 2018, with hiring for packaging, mechanical, sterile, quality assurance and validation beginning in Q1 and late 2018 for the New Albany and Hilliard facilities respectively.
“Our operations in New Albany and Hilliard have played a critical role in the growth of our company, and the investment in our manufacturing, warehouse and R&D capabilities supports that growth,” said PharmaForce Vice President and General Manager Dante Serricchio.
PharmaForce will add approximately 140,000 square feet to its New Albany facility to build out its manufacturing and warehouse operations. The company will also reconfigure and remodel a portion of the existing warehouse and production space. In Hilliard, PharmaForce will remodel and add 1,800 square feet to its existing facility, with plans to invest in new production equipment and supporting infrastructure.
“PharmaForce’s commitment to Hilliard and the jobs the company provides to Columbus Region residents make it an important component to our community’s success,” said David Meadows, economic development director, City of Hilliard.
“We are proud to see PharmaForce expand across the Columbus Region and excited to welcome the growth of its manufacturing capabilities as well as its research and production operations in New Albany,” said Jennifer Chrysler, director of community development, City of New Albany.
“We’re thrilled to partner with PharmaForce on this latest investment, which is a testimony to its talented Ohio employees and effectiveness of its growing Hilliard and New Albany operations,” said JobsOhio Senior Managing Director for Biohealth Aaron Pitts.
About PharmaForce Inc.
PharmaForce Inc., a privately held Columbus, Ohio based pharmaceutical R&D and manufacturing company, was founded in 1999. PharmaForce began as a small team R&D outfit, but quickly expanded to include manufacturing capabilities. In 2009, Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan), acquired PharmaForce. This acquisition allowed for the expansion of the R&D pipeline, increased manufacturing capacity, and an ability to develop a robust pipeline in the fast growing generic injectable market. Today, PharmaForce’s experienced R&D team coupled with state-of-the-art manufacturing capabilities has allowed for a turnkey, complete pharmaceutical operation.
About Columbus 2020
As the economic development organization for the Columbus Region, Columbus 2020’s mission is to generate opportunity and build capacity for economic growth across 11 Central Ohio counties. In 2010, hundreds of business and community leaders developed the Columbus 2020 Regional Growth Strategy, and the Columbus Region is now experiencing the strongest decade of growth in its history. The Columbus 2020 team conducts business outreach, promotes the Columbus Region to market-leading companies around the world, conducts customized research to better understand the Columbus Region’s competitiveness, and works to leverage public, private and institutional partnerships. Funding is received from more than 300 private organizations, local governments, academic institutions and JobsOhio. Learn more at ColumbusRegion.com.